Skip to main content
PMC home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1995 Nov;103(Suppl 8):185–189. doi: 10.1289/ehp.95103s8185

Hormones and breast and endometrial cancers: preventive strategies and future research.

B S Hulka 1, L A Brinton 1
PMCID: PMC1518981  PMID: 8741781

Abstract

A number of hormonal approaches for prevention of endometrial and breast cancers have been proposed. Because of the hormonal responsiveness of both tumors, much attention has focused on effects of exogenous hormone use. Although estrogens in hormone replacement therapy increase the risk of endometrial cancer, the disease is substantially reduced by long-term use of oral contraceptives. The issues with breast cancer are more complex, mainly because of a variety of unresolved effects. Long-term estrogen use is associated with some increase in breast cancer risk, and certain patterns of oral contraceptives appear to predispose to early-onset disease. With respect to estrogens, preventive approaches for both tumors would include use for as limited periods of time as possible. Addition of a progestin appears to lower estrogen-associated endometrial disease, but its effect on breast cancer risk remains less clear. Additional studies on effects of detailed usage parameters should provide useful insights into etiologic mechanisms. Other preventive approaches for endometrial cancer that may work through hormonal mechanisms include staying thin, being physically active, and maintaining a vegetarian diet. Breast cancer risk may possibly be reduced by extended periods of breastfeeding, restriction of intake of alcoholic beverages, remaining thin later in life, and being physically active. Additional research is needed to clarify the biologic mechanisms of these associations. The bridging of epidemiology with the biologic sciences should clarify many unresolved issues and lead to better preventive approaches.

Full text

PDF
189

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong B. K., Brown J. B., Clarke H. T., Crooke D. K., Hähnel R., Masarei J. R., Ratajczak T. Diet and reproductive hormones: a study of vegetarian and nonvegetarian postmenopausal women. J Natl Cancer Inst. 1981 Oct;67(4):761–767. [PubMed] [Google Scholar]
  2. Ballard-Barbash R., Schatzkin A., Carter C. L., Kannel W. B., Kreger B. E., D'Agostino R. B., Splansky G. L., Anderson K. M., Helsel W. E. Body fat distribution and breast cancer in the Framingham Study. J Natl Cancer Inst. 1990 Feb 21;82(4):286–290. doi: 10.1093/jnci/82.4.286. [DOI] [PubMed] [Google Scholar]
  3. Ballard-Barbash R., Schatzkin A., Taylor P. R., Kahle L. L. Association of change in body mass with breast cancer. Cancer Res. 1990 Apr 1;50(7):2152–2155. [PubMed] [Google Scholar]
  4. Barrett-Connor E. Risks and benefits of replacement estrogen. Annu Rev Med. 1992;43:239–251. doi: 10.1146/annurev.me.43.020192.001323. [DOI] [PubMed] [Google Scholar]
  5. Bergkvist L., Adami H. O., Persson I., Hoover R., Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 1989 Aug 3;321(5):293–297. doi: 10.1056/NEJM198908033210505. [DOI] [PubMed] [Google Scholar]
  6. Bernstein L., Henderson B. E., Hanisch R., Sullivan-Halley J., Ross R. K. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst. 1994 Sep 21;86(18):1403–1408. doi: 10.1093/jnci/86.18.1403. [DOI] [PubMed] [Google Scholar]
  7. Brinton L. A., Hoover R. N. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol. 1993 Feb;81(2):265–271. [PubMed] [Google Scholar]
  8. Brinton L. A., Hoover R., Fraumeni J. F., Jr Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer. 1986 Nov;54(5):825–832. doi: 10.1038/bjc.1986.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Brinton L. A. Oral contraceptives and cervical neoplasia. Contraception. 1991 Jun;43(6):581–595. doi: 10.1016/0010-7824(91)90005-z. [DOI] [PubMed] [Google Scholar]
  10. Byers T., Graham S., Rzepka T., Marshall J. Lactation and breast cancer. Evidence for a negative association in premenopausal women. Am J Epidemiol. 1985 May;121(5):664–674. doi: 10.1093/aje/121.5.664. [DOI] [PubMed] [Google Scholar]
  11. Cauley J. A., Gutai J. P., Kuller L. H., LeDonne D., Powell J. G. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol. 1989 Jun;129(6):1120–1131. doi: 10.1093/oxfordjournals.aje.a115234. [DOI] [PubMed] [Google Scholar]
  12. Colditz G. A., Stampfer M. J., Willett W. C., Hunter D. J., Manson J. E., Hennekens C. H., Rosner B. A., Speizer F. E. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control. 1992 Sep;3(5):433–439. doi: 10.1007/BF00051356. [DOI] [PubMed] [Google Scholar]
  13. Cooper J. A., Rohan T. E., Cant E. L., Horsfall D. J., Tilley W. D. Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study. Br J Cancer. 1989 Jan;59(1):119–125. doi: 10.1038/bjc.1989.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ernster V. L., Bush T. L., Huggins G. R., Hulka B. S., Kelsey J. L., Schottenfeld D. Benefits and risks of menopausal estrogen and/or progestin hormone use. Prev Med. 1988 Mar;17(2):201–223. doi: 10.1016/0091-7435(88)90064-3. [DOI] [PubMed] [Google Scholar]
  15. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer. 1988 Dec 15;42(6):832–838. doi: 10.1002/ijc.2910420606. [DOI] [PubMed] [Google Scholar]
  16. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995 Feb;85(2):304–313. doi: 10.1016/0029-7844(94)00383-O. [DOI] [PubMed] [Google Scholar]
  17. Harlap S. The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol. 1992 Jun;166(6 Pt 2):1986–1992. doi: 10.1016/0002-9378(92)91399-u. [DOI] [PubMed] [Google Scholar]
  18. Hemminki E., Kennedy D. L., Baum C., McKinlay S. M. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-86. Am J Public Health. 1988 Nov;78(11):1479–1481. doi: 10.2105/ajph.78.11.1479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Henderson B. E., Ross R. K., Pike M. C. Hormonal chemoprevention of cancer in women. Science. 1993 Jan 29;259(5095):633–638. doi: 10.1126/science.8381558. [DOI] [PubMed] [Google Scholar]
  20. Hildreth N. G., Kelsey J. L., Eisenfeld A. J., LiVolsi V. A., Holford T. R., Fischer D. B. Differences in breast cancer risk factors according to the estrogen receptor level of the tumor. J Natl Cancer Inst. 1983 Jun;70(6):1027–1031. [PubMed] [Google Scholar]
  21. Hillard T. C., Whitcroft S., Ellerington M. C., Whitehead M. I. The long-term risks and benefits of hormone replacement therapy. J Clin Pharm Ther. 1991 Aug;16(4):231–245. doi: 10.1111/j.1365-2710.1991.tb00310.x. [DOI] [PubMed] [Google Scholar]
  22. Hoover R., Glass A., Finkle W. D., Azevedo D., Milne K. Conjugated estrogens and breast cancer risk in women. J Natl Cancer Inst. 1981 Oct;67(4):815–820. [PubMed] [Google Scholar]
  23. Hulka B. S., Chambless L. E., Deubner D. C., Wilkinson W. E. Breast cancer and estrogen replacement therapy. Am J Obstet Gynecol. 1982 Jul 15;143(6):638–644. doi: 10.1016/0002-9378(82)90108-9. [DOI] [PubMed] [Google Scholar]
  24. Hulka B. S., Chambless L. E., Kaufman D. G., Fowler W. C., Jr, Greenberg B. G. Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA. 1982 Jan 22;247(4):475–477. [PubMed] [Google Scholar]
  25. Hulka B. S., Chambless L. E., Wilkinson W. E., Deubner D. C., McCarty K. S., Sr, McCarty K. S., Jr Hormonal and personal effects on estrogen receptors in breast cancer. Am J Epidemiol. 1984 May;119(5):692–704. doi: 10.1093/oxfordjournals.aje.a113790. [DOI] [PubMed] [Google Scholar]
  26. Hulka B. S., Fowler W. C., Jr, Kaufman D. G., Grimson R. C., Greenberg B. G., Hogue C. J., Berger G. S., Pulliam C. C. Estrogen and endometrial cancer: cases and two control groups from North Carolina. Am J Obstet Gynecol. 1980 May 1;137(1):92–101. doi: 10.1016/0002-9378(80)90391-9. [DOI] [PubMed] [Google Scholar]
  27. Hunter D. J., Kelsey K. T. Pesticide residues and breast cancer: the harvest of a silent spring? J Natl Cancer Inst. 1993 Apr 21;85(8):598–599. doi: 10.1093/jnci/85.8.598. [DOI] [PubMed] [Google Scholar]
  28. Hunter D. J., Willett W. C. Diet, body size, and breast cancer. Epidemiol Rev. 1993;15(1):110–132. doi: 10.1093/oxfordjournals.epirev.a036096. [DOI] [PubMed] [Google Scholar]
  29. Kaufman D. W., Shapiro S., Slone D., Rosenberg L., Miettinen O. S., Stolley P. D., Knapp R. C., Leavitt T., Jr, Watring W. G., Rosenshein N. B. Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med. 1980 Oct 30;303(18):1045–1047. doi: 10.1056/NEJM198010303031807. [DOI] [PubMed] [Google Scholar]
  30. Miller D. R., Rosenberg L., Kaufman D. W., Stolley P., Warshauer M. E., Shapiro S. Breast cancer before age 45 and oral contraceptive use: new findings. Am J Epidemiol. 1989 Feb;129(2):269–280. doi: 10.1093/oxfordjournals.aje.a115132. [DOI] [PubMed] [Google Scholar]
  31. Mills P. K., Beeson W. L., Phillips R. L., Fraser G. E. Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer. 1989 Aug 1;64(3):591–597. doi: 10.1002/1097-0142(19890801)64:3<591::aid-cncr2820640305>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  32. Nayfield S. G., Karp J. E., Ford L. G., Dorr F. A., Kramer B. S. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst. 1991 Oct 16;83(20):1450–1459. doi: 10.1093/jnci/83.20.1450. [DOI] [PubMed] [Google Scholar]
  33. Newcomb P. A., Storer B. E., Longnecker M. P., Mittendorf R., Greenberg E. R., Clapp R. W., Burke K. P., Willett W. C., MacMahon B. Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med. 1994 Jan 13;330(2):81–87. doi: 10.1056/NEJM199401133300201. [DOI] [PubMed] [Google Scholar]
  34. Paterson M. E., Wade-Evans T., Sturdee D. W., Thom M. H., Studd J. W. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Br Med J. 1980 Mar 22;280(6217):822–824. doi: 10.1136/bmj.280.6217.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Pike M. C., Spicer D. V. The chemoprevention of breast cancer by reducing sex steroid exposure: perspectives from epidemiology. J Cell Biochem Suppl. 1993;17G:26–36. doi: 10.1002/jcb.240531105. [DOI] [PubMed] [Google Scholar]
  36. Rookus M. A., van Leeuwen F. E. Oral contraceptives and risk of breast cancer in women aged 20-54 years. Netherlands Oral Contraceptives and Breast Cancer Study Group. Lancet. 1994 Sep 24;344(8926):844–851. doi: 10.1016/s0140-6736(94)92826-6. [DOI] [PubMed] [Google Scholar]
  37. Ross R. K., Paganini-Hill A., Gerkins V. R., Mack T. M., Pfeffer R., Arthur M., Henderson B. E. A case-control study of menopausal estrogen therapy and breast cancer. JAMA. 1980 Apr 25;243(16):1635–1639. [PubMed] [Google Scholar]
  38. Schwartzbaum J. A., Hulka B. S., Fowler W. C., Jr, Kaufman D. G., Hoberman D. The influence of exogenous estrogen use on survival after diagnosis of endometrial cancer. Am J Epidemiol. 1987 Nov;126(5):851–860. doi: 10.1093/oxfordjournals.aje.a114722. [DOI] [PubMed] [Google Scholar]
  39. Shapiro S., Kelly J. P., Rosenberg L., Kaufman D. W., Helmrich S. P., Rosenshein N. B., Lewis J. L., Jr, Knapp R. C., Stolley P. D., Schottenfeld D. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med. 1985 Oct 17;313(16):969–972. doi: 10.1056/NEJM198510173131601. [DOI] [PubMed] [Google Scholar]
  40. Sturgeon S. R., Brinton L. A., Berman M. L., Mortel R., Twiggs L. B., Barrett R. J., Wilbanks G. D. Past and present physical activity and endometrial cancer risk. Br J Cancer. 1993 Sep;68(3):584–589. doi: 10.1038/bjc.1993.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Voigt L. F., Weiss N. S., Chu J., Daling J. R., McKnight B., van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet. 1991 Aug 3;338(8762):274–277. doi: 10.1016/0140-6736(91)90417-n. [DOI] [PubMed] [Google Scholar]
  42. Weiss N. S., Sayvetz T. A. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med. 1980 Mar 6;302(10):551–554. doi: 10.1056/NEJM198003063021004. [DOI] [PubMed] [Google Scholar]
  43. Weiss N. S., Szekely D. R., English D. R., Schweid A. I. Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA. 1979 Jul 20;242(3):261–264. [PubMed] [Google Scholar]
  44. White E., Malone K. E., Weiss N. S., Daling J. R. Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst. 1994 Apr 6;86(7):505–514. doi: 10.1093/jnci/86.7.505. [DOI] [PubMed] [Google Scholar]
  45. Yang C. P., Daling J. R., Band P. R., Gallagher R. P., White E., Weiss N. S. Noncontraceptive hormone use and risk of breast cancer. Cancer Causes Control. 1992 Sep;3(5):475–479. doi: 10.1007/BF00051360. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES